"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shack...
Ep175: Andy Scharenberg on in vivo CAR-T cell therapies
Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.
--------
1:10:46
Ep174: Najat Khan on the TechBio Movement
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.
--------
1:07:16
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.
--------
57:56
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
--------
1:20:53
Ep171: Ram Aiyar on RNA Editing Medicines
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
New Zealand